期刊文献+

金属蛋白酶抑制剂BB-94抑制Lewis肺癌生长和转移的实验研究 被引量:2

AN EXPERIMENTAL STUDY OF MATRIX METALLOPROTEINASE INHIBITOR BB-94 ON TUMOR GROWTH AND METASTASIS OF LEWIS LUNG CARCINOMA
下载PDF
导出
摘要 AIM To study the inhibition effect of matrix metalloproteinase inhibitor BB 94 on tumor growth and metastasis using Lweis lung carcinoma. METHODS Lewis lung carcinoma cell suspension [cancer tissue (g)∶physiological saline(mL) equal to 1∶3 ] were inoculated subcutaneously to 20 mice, they were randomized into 2 groups. From the 2nd day, the treated group was given BB 94 30 mg·kg -1 ip once daily (20 times) and the control group was given vehicle only (phosphate buffered saline, pH 7 4, containing 0 01% Tween 80). On the 22nd day, the weight of the subcutaneous tumor and the lung metastasis rates of the two groups were detected. The results were analyzed by Student t and x 2 test. RESULTS The subcutaneous tumor weight of the control and BB 94 treated group were found to be (6 75±1 45) g and (3 16±1 88) g, respectively( P <0 001). The rate of lung metastasis of the control and treated group was 80%(8/10) and 30%(3/10), respectively( P <0 05). CONCLUSION These results suggest that the matrix metalloproteinase inhibitor BB 94 has strong inhibitory effect both on growth of the primary tumor and pulmonary metastasis of Lewis lung carcinoma. AIM To study the inhibition effect of matrix metalloproteinase inhibitor BB 94 on tumor growth and metastasis using Lweis lung carcinoma. METHODS Lewis lung carcinoma cell suspension [cancer tissue (g)∶physiological saline(mL) equal to 1∶3 ] were inoculated subcutaneously to 20 mice, they were randomized into 2 groups. From the 2nd day, the treated group was given BB 94 30 mg·kg -1 ip once daily (20 times) and the control group was given vehicle only (phosphate buffered saline, pH 7 4, containing 0 01% Tween 80). On the 22nd day, the weight of the subcutaneous tumor and the lung metastasis rates of the two groups were detected. The results were analyzed by Student t and x 2 test. RESULTS The subcutaneous tumor weight of the control and BB 94 treated group were found to be (6 75±1 45) g and (3 16±1 88) g, respectively( P <0 001). The rate of lung metastasis of the control and treated group was 80%(8/10) and 30%(3/10), respectively( P <0 05). CONCLUSION These results suggest that the matrix metalloproteinase inhibitor BB 94 has strong inhibitory effect both on growth of the primary tumor and pulmonary metastasis of Lewis lung carcinoma.
出处 《药学学报》 CAS CSCD 北大核心 2000年第6期473-475,共3页 Acta Pharmaceutica Sinica
关键词 金属蛋白酶抑制剂BB-94 肿瘤转移 Lewis肺肿瘤 lung neoplasm matrix metalloproteinase inhibitor(BB 94) neoplasm metastasis
  • 相关文献

参考文献3

  • 1李红梅,中华医学杂志,1997年,77卷,652页
  • 2Wang X,Cancer Res,1994年,54卷,4726页
  • 3Zhou K X,中华医学杂志,1994年,74卷,402页

同被引文献41

  • 1周可祥,吴秉铨,郑杰,王洁良,由江峰,崔湘琳.TIMP-1基因转染对人肺巨细胞癌细胞系生物学行为的影响[J].中华医学杂志,1994,74(7):402-405. 被引量:13
  • 2Vallee BL, Auld DS. Zinc coordination, function and structure of zinc enymes and other proteins [ J ]. Biochemistry, 1990,29(24) :5647 -5659.
  • 3Fanchon S, Bourd K, Septier D, et al. Involvement of matrix metalloproteinases in the onset of dentin mineralization[J].Eur J Oral Sci,2004,112(2) :171 -176.
  • 4Onoda T, Ono T, Dhar DK, et al. Doxycycline inhibits cell proliferation and invasive potential:combination therapy with cyclooxygenase -2 inhibitor in human colorectal cancer cells [J]. J Lab Chn Med,2004,143(4) :207 -216.
  • 5Lokeshwar BL. MMP inhibition in prostate cancer[ J ]. Ann New York Acad Sci, 1999,878:271 - 289.
  • 6Sparano JA, Bemardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first - hne chemotherapy: Eastern Cooperative Oncology Group trial E2196[J]. J Clin Oncol,2004,22(23) : 4683 - 4690.
  • 7Wimmel A, Schilli M, Kaiser U, et al, Preferential histotypic expression of CD44 isoforms in human lung cancer[J]. Lung Cancer, 1997,16(2-3): 151.
  • 8Jackson D G, Schenker T, aibee R, et al. Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas[J]. Int J Cancer, 1994, 8(Suppl):110.
  • 9Tran T A, Kallakury B V S, Sheehan C E, et al. Expression of cd44 standard from and variant isoforms in non-small cell lung carcinomas[J]. Human Pathol, 1997, 28(7): 809.
  • 10Hirata T, Fukuse T, Naiki H, et al. Expression of CD44 variant exon 6 in stage Ⅰ non-small cell lung carcinoma as a prognostic factor [J].Cancer Res, 1998, 58(6): 1108.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部